(Q33388044)

26 July 2017

title

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience (English)

1 reference

systemic lupus erythematosus

26 July 2017

0 references

1 reference

0 references

author name string

A Lateef

1

1 reference

26 July 2017

M Lahiri

2

1 reference

26 July 2017

G G Teng

3

1 reference

26 July 2017

S Vasoo

4

1 reference

26 July 2017

language of work or name

1 reference

29 January 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

19

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

765-770

1 reference

Systemic lupus erythematosus.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Use of rituximab in patients with systemic lupus erythematosus: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

High rate of death caused by systemic lupus erythematosus among U. S. residents of Asian descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358599

21 January 2018

Identifiers

DOI

10.1177/0961203309358599

1 reference

26 July 2017

1 reference